Dosing & Uses
Available in combination with trimethoprim
See trimethoprim/sulfamethoxazole
Interactions
Interaction Checker
No Results
Contraindicated
Serious
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious (35)
- aminobenzoate potassium
aminobenzoate potassium decreases effects of sulfamethoxazole by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- aminolevulinic acid oral
aminolevulinic acid oral, sulfamethoxazole. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period.
- aminolevulinic acid topical
sulfamethoxazole, aminolevulinic acid topical. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other.
- amiodarone
amiodarone and sulfamethoxazole both increase QTc interval. Avoid or Use Alternate Drug.
- antithrombin alfa
sulfamethoxazole increases effects of antithrombin alfa by decreasing metabolism. Avoid or Use Alternate Drug.
sulfamethoxazole increases effects of antithrombin alfa by plasma protein binding competition. Avoid or Use Alternate Drug. - antithrombin III
sulfamethoxazole increases effects of antithrombin III by decreasing metabolism. Avoid or Use Alternate Drug.
sulfamethoxazole increases effects of antithrombin III by plasma protein binding competition. Avoid or Use Alternate Drug. - argatroban
sulfamethoxazole increases effects of argatroban by decreasing metabolism. Avoid or Use Alternate Drug.
sulfamethoxazole increases effects of argatroban by plasma protein binding competition. Avoid or Use Alternate Drug. - BCG vaccine live
sulfamethoxazole decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.
- bemiparin
sulfamethoxazole increases effects of bemiparin by decreasing metabolism. Avoid or Use Alternate Drug.
sulfamethoxazole increases effects of bemiparin by plasma protein binding competition. Avoid or Use Alternate Drug. - bivalirudin
sulfamethoxazole increases effects of bivalirudin by decreasing metabolism. Avoid or Use Alternate Drug.
sulfamethoxazole increases effects of bivalirudin by plasma protein binding competition. Avoid or Use Alternate Drug. - dalteparin
sulfamethoxazole increases effects of dalteparin by decreasing metabolism. Avoid or Use Alternate Drug.
sulfamethoxazole increases effects of dalteparin by plasma protein binding competition. Avoid or Use Alternate Drug. - disopyramide
sulfamethoxazole and disopyramide both increase QTc interval. Avoid or Use Alternate Drug.
- enoxaparin
sulfamethoxazole increases effects of enoxaparin by decreasing metabolism. Avoid or Use Alternate Drug.
sulfamethoxazole increases effects of enoxaparin by plasma protein binding competition. Avoid or Use Alternate Drug. - erdafitinib
sulfamethoxazole will increase the level or effect of erdafitinib by affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with strong CYP2C9 inhibitors, monitor closely for adverse reactions and consider decreasing dose accordingly. If strong CYP2C9 inhibitor is discontinued, consider increasing erdafitinib dose in the absence of any drug-related toxicities.
- fondaparinux
sulfamethoxazole increases effects of fondaparinux by decreasing metabolism. Avoid or Use Alternate Drug.
sulfamethoxazole increases effects of fondaparinux by plasma protein binding competition. Avoid or Use Alternate Drug. - heparin
sulfamethoxazole increases effects of heparin by decreasing metabolism. Avoid or Use Alternate Drug.
sulfamethoxazole increases effects of heparin by plasma protein binding competition. Avoid or Use Alternate Drug. - ibutilide
sulfamethoxazole and ibutilide both increase QTc interval. Avoid or Use Alternate Drug.
- indapamide
sulfamethoxazole and indapamide both increase QTc interval. Avoid or Use Alternate Drug.
- mefloquine
mefloquine increases toxicity of sulfamethoxazole by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.
- methenamine
methenamine, sulfamethoxazole. Other (see comment). Contraindicated. Comment: This combination may form an insoluble precipitate in the urine, decreasing the effects of both agents.
- methotrexate
sulfamethoxazole increases toxicity of methotrexate by plasma protein binding competition. Avoid or Use Alternate Drug. Methotrexate concentrations may be elevated, increasing the risk of toxicity (eg, bone marrow suppression).
- methyl aminolevulinate
sulfamethoxazole, methyl aminolevulinate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other.
- pentamidine
sulfamethoxazole and pentamidine both increase QTc interval. Avoid or Use Alternate Drug.
- pexidartinib
sulfamethoxazole and pexidartinib both increase inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity.
- phenindione
sulfamethoxazole increases effects of phenindione by decreasing metabolism. Avoid or Use Alternate Drug.
sulfamethoxazole increases effects of phenindione by plasma protein binding competition. Avoid or Use Alternate Drug. - pimozide
sulfamethoxazole and pimozide both increase QTc interval. Avoid or Use Alternate Drug.
- pretomanid
sulfamethoxazole, pretomanid. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid.
- procainamide
sulfamethoxazole and procainamide both increase QTc interval. Avoid or Use Alternate Drug.
- protamine
sulfamethoxazole increases effects of protamine by decreasing metabolism. Avoid or Use Alternate Drug.
sulfamethoxazole increases effects of protamine by plasma protein binding competition. Avoid or Use Alternate Drug. - quinidine
quinidine and sulfamethoxazole both increase QTc interval. Avoid or Use Alternate Drug.
- siponimod
sulfamethoxazole will increase the level or effect of siponimod by affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug. Coadministration of siponimod with drugs that cause moderate CYP2C9 AND a moderate or strong CYP3A4 inhibition is not recommended. Caution if siponimod coadministered with moderate CYP2C9 inhibitors alone.
- sotalol
sulfamethoxazole and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
- tretinoin
sulfamethoxazole, tretinoin. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.
- tretinoin topical
sulfamethoxazole, tretinoin topical. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.
- typhoid vaccine live
sulfamethoxazole decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.
Monitor Closely (113)
- amantadine
sulfamethoxazole increases levels of amantadine by decreasing elimination. Use Caution/Monitor. Coadministration may impair renal clearance of amantadine, resulting in higher plasma concentrations.
- amiodarone
amiodarone will increase the level or effect of sulfamethoxazole by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
- amitriptyline
amitriptyline and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- amoxapine
amoxapine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- artemether/lumefantrine
sulfamethoxazole and artemether/lumefantrine both increase QTc interval. Modify Therapy/Monitor Closely.
- aspirin
aspirin, sulfamethoxazole. Either increases effects of the other by plasma protein binding competition. Use Caution/Monitor. Due to high protein binding capacity of both drugs, one may displace the other when coadministered leading to an enhanced effect of the displaced drug; risk is low with low dose aspirin.
- aspirin/citric acid/sodium bicarbonate
aspirin/citric acid/sodium bicarbonate, sulfamethoxazole. Either increases effects of the other by plasma protein binding competition. Use Caution/Monitor. Due to high protein binding capacity of both drugs, one may displace the other when coadministered leading to an enhanced effect of the displaced drug; risk is low with low dose aspirin.
- bazedoxifene/conjugated estrogens
sulfamethoxazole will decrease the level or effect of bazedoxifene/conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- carvedilol
sulfamethoxazole will increase the level or effect of carvedilol by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
- chlorpromazine
chlorpromazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- cimetidine
cimetidine will increase the level or effect of sulfamethoxazole by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
- clarithromycin
clarithromycin and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- clomipramine
clomipramine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- conjugated estrogens
sulfamethoxazole will decrease the level or effect of conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- cyclosporine
sulfamethoxazole, cyclosporine. Either increases effects of the other by nephrotoxicity and/or ototoxicity. Use Caution/Monitor.
- dapsone topical
sulfamethoxazole increases toxicity of dapsone topical by decreasing metabolism. Modify Therapy/Monitor Closely. Coadministration increases systemic exposure of dapsone and its metabolites (N-acetyl-dapsone, dapsone hydroxylamine). May induce methemoglobinemia.
- desipramine
desipramine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- digoxin
sulfamethoxazole will increase the level or effect of digoxin by altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.
sulfamethoxazole will increase the level or effect of digoxin by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor. - dofetilide
sulfamethoxazole will increase the level or effect of dofetilide by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
sulfamethoxazole and dofetilide both increase QTc interval. Modify Therapy/Monitor Closely. - dolasetron
sulfamethoxazole and dolasetron both increase QTc interval. Use Caution/Monitor.
- doxepin
doxepin and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- dronabinol
sulfamethoxazole will increase the level or effect of dronabinol by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Dronabinol is a CYP2C9 substrate.
- dronedarone
sulfamethoxazole and dronedarone both increase QTc interval. Modify Therapy/Monitor Closely.
- droperidol
sulfamethoxazole and droperidol both increase QTc interval. Modify Therapy/Monitor Closely.
- efavirenz
efavirenz will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
- eltrombopag
sulfamethoxazole will increase the level or effect of eltrombopag by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
- eluxadoline
sulfamethoxazole increases levels of eluxadoline by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP2C9/10 inhibitors.
- epinephrine
epinephrine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- epinephrine racemic
epinephrine racemic and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- erythromycin base
sulfamethoxazole and erythromycin base both increase QTc interval. Modify Therapy/Monitor Closely.
- erythromycin ethylsuccinate
sulfamethoxazole and erythromycin ethylsuccinate both increase QTc interval. Modify Therapy/Monitor Closely.
- erythromycin lactobionate
sulfamethoxazole and erythromycin lactobionate both increase QTc interval. Modify Therapy/Monitor Closely.
- erythromycin stearate
sulfamethoxazole and erythromycin stearate both increase QTc interval. Modify Therapy/Monitor Closely.
- estradiol
sulfamethoxazole will decrease the level or effect of estradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- estrogens conjugated synthetic
sulfamethoxazole will decrease the level or effect of estrogens conjugated synthetic by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- estropipate
sulfamethoxazole will decrease the level or effect of estropipate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- ethinylestradiol
sulfamethoxazole will decrease the level or effect of ethinylestradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- ethotoin
sulfamethoxazole will increase the level or effect of ethotoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
- etravirine
sulfamethoxazole will increase the level or effect of etravirine by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
- flecainide
sulfamethoxazole and flecainide both increase QTc interval. Use Caution/Monitor.
- fluconazole
sulfamethoxazole and fluconazole both increase QTc interval. Modify Therapy/Monitor Closely.
- fluoxetine
fluoxetine will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
- fluphenazine
fluphenazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- fluvoxamine
fluvoxamine and sulfamethoxazole both increase QTc interval. Use Caution/Monitor.
- formoterol
sulfamethoxazole and formoterol both increase QTc interval. Modify Therapy/Monitor Closely.
- foscarnet
sulfamethoxazole and foscarnet both increase QTc interval. Use Caution/Monitor.
- fosphenytoin
sulfamethoxazole will increase the level or effect of fosphenytoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
- glimepiride
sulfamethoxazole increases levels of glimepiride by plasma protein binding competition. Use Caution/Monitor.
- glipizide
sulfamethoxazole increases levels of glipizide by plasma protein binding competition. Use Caution/Monitor.
- glucarpidase
glucarpidase will decrease the level or effect of sulfamethoxazole by increasing metabolism. Modify Therapy/Monitor Closely. Leucorvorin, reduced folates, and folate antimetabolites are substrates for glucarpidase (hydrolyzes glutamate residue from folic acid and antifolates)
- glyburide
sulfamethoxazole increases levels of glyburide by plasma protein binding competition. Use Caution/Monitor.
sulfamethoxazole increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism. - haloperidol
sulfamethoxazole and haloperidol both increase QTc interval. Modify Therapy/Monitor Closely.
- iloperidone
sulfamethoxazole and iloperidone both increase QTc interval. Use Caution/Monitor.
- imatinib
imatinib will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
- imidapril
sulfamethoxazole, imidapril. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.
- imipramine
imipramine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- itraconazole
sulfamethoxazole and itraconazole both increase QTc interval. Modify Therapy/Monitor Closely.
- ketoconazole
sulfamethoxazole and ketoconazole both increase QTc interval. Modify Therapy/Monitor Closely.
- lacosamide
sulfamethoxazole increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- lapatinib
sulfamethoxazole and lapatinib both increase QTc interval. Use Caution/Monitor.
- lesinurad (DSC)
sulfamethoxazole will increase the level or effect of lesinurad (DSC) by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- levofloxacin
sulfamethoxazole and levofloxacin both increase QTc interval. Use Caution/Monitor.
- levoketoconazole
sulfamethoxazole and levoketoconazole both increase QTc interval. Modify Therapy/Monitor Closely.
- levonorgestrel oral/ethinylestradiol/ferrous bisglycinate
sulfamethoxazole will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy.
- lofepramine
lofepramine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- losartan
sulfamethoxazole will increase the level or effect of losartan by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.
- lumefantrine
sulfamethoxazole and lumefantrine both increase QTc interval. Modify Therapy/Monitor Closely.
- maprotiline
maprotiline and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- mestranol
sulfamethoxazole will decrease the level or effect of mestranol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- methadone
sulfamethoxazole and methadone both increase QTc interval. Use Caution/Monitor.
- methoxsalen
methoxsalen, sulfamethoxazole. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects.
- metronidazole
metronidazole, sulfamethoxazole. Mechanism: decreasing metabolism. Use Caution/Monitor. Disulfiram like reaction.
- mipomersen
mipomersen, sulfamethoxazole. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.
- moxifloxacin
sulfamethoxazole and moxifloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- nateglinide
sulfamethoxazole will increase the level or effect of nateglinide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
sulfamethoxazole increases levels of nateglinide by plasma protein binding competition. Use Caution/Monitor. - nilotinib
sulfamethoxazole and nilotinib both increase QTc interval. Modify Therapy/Monitor Closely.
- nortriptyline
nortriptyline and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- octreotide
sulfamethoxazole and octreotide both increase QTc interval. Modify Therapy/Monitor Closely.
- octreotide (Antidote)
sulfamethoxazole and octreotide (Antidote) both increase QTc interval. Modify Therapy/Monitor Closely.
- ofloxacin
sulfamethoxazole and ofloxacin both increase QTc interval. Use Caution/Monitor.
- ospemifene
sulfamethoxazole increases levels of ospemifene by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
sulfamethoxazole, ospemifene. Either increases levels of the other by plasma protein binding competition. Modify Therapy/Monitor Closely. - paliperidone
sulfamethoxazole and paliperidone both increase QTc interval. Use Caution/Monitor.
- parecoxib
sulfamethoxazole will increase the level or effect of parecoxib by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
- paroxetine
sulfamethoxazole and paroxetine both increase QTc interval. Use Caution/Monitor.
- perphenazine
perphenazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- phenytoin
sulfamethoxazole will increase the level or effect of phenytoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
- porfimer
sulfamethoxazole, porfimer. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced photosensitivity.
- posaconazole
sulfamethoxazole and posaconazole both increase QTc interval. Use Caution/Monitor.
- pralatrexate
sulfamethoxazole increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor.
- procainamide
sulfamethoxazole will increase the level or effect of procainamide by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
- prochlorperazine
prochlorperazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- promazine
promazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
promazine increases toxicity of sulfamethoxazole by unspecified interaction mechanism. Use Caution/Monitor. Enhanced myelosuppression. - promethazine
promethazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- protriptyline
protriptyline and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- quinidine
quinidine will increase the level or effect of sulfamethoxazole by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
- ranolazine
sulfamethoxazole and ranolazine both increase QTc interval. Use Caution/Monitor.
- repaglinide
sulfamethoxazole increases levels of repaglinide by plasma protein binding competition. Use Caution/Monitor.
- risperidone
sulfamethoxazole and risperidone both increase QTc interval. Use Caution/Monitor.
- sodium picosulfate/magnesium oxide/anhydrous citric acid
sulfamethoxazole decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.
- tamoxifen
sulfamethoxazole, tamoxifen. affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. CYP2C9/10 inhibition decreases tamoxifen metabolism to active metabolites.
- telavancin
sulfamethoxazole and telavancin both increase QTc interval. Use Caution/Monitor.
- terbinafine
sulfamethoxazole will increase the level or effect of terbinafine by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
- thioridazine
thioridazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- trazodone
trazodone and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- trifluoperazine
trifluoperazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- trimethoprim
sulfamethoxazole and trimethoprim both increase QTc interval. Use Caution/Monitor.
- trimipramine
trimipramine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- tropisetron
sulfamethoxazole and tropisetron both increase QTc interval. Use Caution/Monitor.
- valoctocogene roxaparvovec
sulfamethoxazole and valoctocogene roxaparvovec both increase Other (see comment). Use Caution/Monitor. Medications that may cause hepatotoxicity when combined with valoctogene roxaparvovec may potentiate the risk of elevated liver enzymes. Closely monitor these medications and consider alternative medications in case of potential drug interactions.
- venlafaxine
sulfamethoxazole and venlafaxine both increase QTc interval. Use Caution/Monitor.
- voriconazole
sulfamethoxazole and voriconazole both increase QTc interval. Use Caution/Monitor.
- warfarin
sulfamethoxazole will increase the level or effect of warfarin by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Mechanism of interaction may be caused by CYP2C9 inhibition and protein-binding displacement. If coadministered, consider decreasing warfarin dose by 10-20%.
- ziprasidone
sulfamethoxazole and ziprasidone both increase QTc interval. Modify Therapy/Monitor Closely.
Minor (117)
- alosetron
sulfamethoxazole will increase the level or effect of alosetron by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- amiloride
amiloride, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.
amiloride increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown. - aminohippurate sodium
sulfamethoxazole, aminohippurate sodium. Other (see comment). Minor/Significance Unknown. Comment: This substance interferes with chemical color development of aminohippurate (PAH) essential to accurate renal clearance analysis.
- amiodarone
amiodarone will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- amitriptyline
sulfamethoxazole decreases levels of amitriptyline by unspecified interaction mechanism. Minor/Significance Unknown.
- amobarbital
amobarbital will decrease the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- amoxapine
sulfamethoxazole decreases levels of amoxapine by unspecified interaction mechanism. Minor/Significance Unknown.
- aspirin rectal
aspirin rectal increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- aspirin/citric acid/sodium bicarbonate
aspirin/citric acid/sodium bicarbonate increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- azathioprine
sulfamethoxazole, azathioprine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Leukopenia due to additive myelosuppression.
- azithromycin
azithromycin and sulfamethoxazole both increase QTc interval. Minor/Significance Unknown.
- balsalazide
sulfamethoxazole will decrease the level or effect of balsalazide by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
balsalazide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown. - bendroflumethiazide
bendroflumethiazide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
bendroflumethiazide, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia. - biotin
sulfamethoxazole will decrease the level or effect of biotin by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- bosentan
sulfamethoxazole will increase the level or effect of bosentan by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- bumetanide
bumetanide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- butabarbital
butabarbital will decrease the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- butalbital
butalbital will decrease the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- carbamazepine
carbamazepine will decrease the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- celecoxib
sulfamethoxazole will increase the level or effect of celecoxib by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- chlorothiazide
chlorothiazide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
chlorothiazide, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia. - chlorthalidone
chlorthalidone increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
chlorthalidone, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia. - choline magnesium trisalicylate
choline magnesium trisalicylate increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- cimetidine
cimetidine will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- clomipramine
sulfamethoxazole decreases levels of clomipramine by unspecified interaction mechanism. Minor/Significance Unknown.
- cyclopenthiazide
cyclopenthiazide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
cyclopenthiazide, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia. - dapsone
sulfamethoxazole, dapsone. Either increases levels of the other by decreasing elimination. Minor/Significance Unknown.
- desipramine
sulfamethoxazole decreases levels of desipramine by unspecified interaction mechanism. Minor/Significance Unknown.
- diclofenac
sulfamethoxazole will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- diflunisal
diflunisal increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- diltiazem
sulfamethoxazole will increase the level or effect of diltiazem by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- disulfiram
disulfiram will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- dosulepin
sulfamethoxazole decreases levels of dosulepin by unspecified interaction mechanism. Minor/Significance Unknown.
- doxepin
sulfamethoxazole decreases levels of doxepin by unspecified interaction mechanism. Minor/Significance Unknown.
- drospirenone
drospirenone, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.
drospirenone increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown. - ethacrynic acid
ethacrynic acid increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- ethotoin
sulfamethoxazole increases levels of ethotoin by decreasing metabolism. Minor/Significance Unknown.
- etravirine
etravirine will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- felbamate
felbamate will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- fluconazole
fluconazole will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- flurbiprofen
sulfamethoxazole will increase the level or effect of flurbiprofen by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- fluvastatin
sulfamethoxazole will increase the level or effect of fluvastatin by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- folic acid
sulfamethoxazole decreases levels of folic acid by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- fosphenytoin
sulfamethoxazole increases levels of fosphenytoin by decreasing metabolism. Minor/Significance Unknown.
- furosemide
furosemide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- ganciclovir
ganciclovir increases toxicity of sulfamethoxazole by pharmacodynamic synergism. Minor/Significance Unknown.
- hydrochlorothiazide
sulfamethoxazole will increase the level or effect of hydrochlorothiazide by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
hydrochlorothiazide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
hydrochlorothiazide, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia. - ibuprofen
sulfamethoxazole will increase the level or effect of ibuprofen by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- ibuprofen IV
sulfamethoxazole will increase the level or effect of ibuprofen IV by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- imipramine
sulfamethoxazole decreases levels of imipramine by unspecified interaction mechanism. Minor/Significance Unknown.
- indapamide
indapamide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
indapamide, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia. - indomethacin
indomethacin increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- isocarboxazid
isocarboxazid increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- ketoconazole
ketoconazole will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- L-methylfolate
sulfamethoxazole decreases levels of L-methylfolate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- lamivudine
sulfamethoxazole increases levels of lamivudine by decreasing renal clearance. Minor/Significance Unknown.
- leflunomide
leflunomide will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- levoketoconazole
levoketoconazole will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- linezolid
linezolid increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- lofepramine
sulfamethoxazole decreases levels of lofepramine by unspecified interaction mechanism. Minor/Significance Unknown.
- losartan
sulfamethoxazole decreases effects of losartan by decreasing metabolism. Minor/Significance Unknown. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.
- maprotiline
sulfamethoxazole decreases levels of maprotiline by unspecified interaction mechanism. Minor/Significance Unknown.
- meloxicam
sulfamethoxazole will increase the level or effect of meloxicam by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- memantine
sulfamethoxazole will increase the level or effect of memantine by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- mesalamine
mesalamine increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- metformin
sulfamethoxazole will increase the level or effect of metformin by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- methyclothiazide
sulfamethoxazole will increase the level or effect of methyclothiazide by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
methyclothiazide, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia. - metolazone
metolazone increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
metolazone, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia. - metronidazole
metronidazole will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- miconazole vaginal
miconazole vaginal will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- midodrine
sulfamethoxazole will increase the level or effect of midodrine by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- mineral oil
mineral oil decreases levels of sulfamethoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- nateglinide
nateglinide will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- nilotinib
nilotinib will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- nitazoxanide
nitazoxanide, sulfamethoxazole. Either increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown.
- nortriptyline
sulfamethoxazole decreases levels of nortriptyline by unspecified interaction mechanism. Minor/Significance Unknown.
- ofloxacin
sulfamethoxazole will increase the level or effect of ofloxacin by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- pantothenic acid
sulfamethoxazole will decrease the level or effect of pantothenic acid by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- pazopanib
sulfamethoxazole and pazopanib both increase QTc interval. Minor/Significance Unknown.
- pentobarbital
pentobarbital will decrease the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- phenelzine
phenelzine increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- phenobarbital
phenobarbital will decrease the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- phenytoin
sulfamethoxazole increases levels of phenytoin by decreasing metabolism. Minor/Significance Unknown.
- pimozide
sulfamethoxazole decreases levels of pimozide by unspecified interaction mechanism. Minor/Significance Unknown.
- piroxicam
sulfamethoxazole will increase the level or effect of piroxicam by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- primaquine
primaquine, sulfamethoxazole. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hemolysis in G6PD deficient pts.
- primidone
primidone will decrease the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- probenecid
probenecid increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- protriptyline
sulfamethoxazole decreases levels of protriptyline by unspecified interaction mechanism. Minor/Significance Unknown.
- pyridoxine
sulfamethoxazole will decrease the level or effect of pyridoxine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- pyridoxine (Antidote)
sulfamethoxazole will decrease the level or effect of pyridoxine (Antidote) by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- pyrimethamine
sulfamethoxazole, pyrimethamine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased bone marrow toxicity.
- quinine
sulfamethoxazole will increase the level or effect of quinine by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- ramelteon
sulfamethoxazole will increase the level or effect of ramelteon by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- rifampin
rifampin will decrease the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- rifapentine
rifapentine will decrease the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- salicylates (non-asa)
salicylates (non-asa) increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- salsalate
salsalate increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- selegiline transdermal
selegiline transdermal increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- spironolactone
spironolactone, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.
spironolactone increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown. - sulfasalazine
sulfasalazine increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- thiamine
sulfamethoxazole will decrease the level or effect of thiamine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- ticlopidine
ticlopidine will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- torsemide
torsemide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- tranylcypromine
tranylcypromine increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- trazodone
sulfamethoxazole decreases levels of trazodone by unspecified interaction mechanism. Minor/Significance Unknown.
- triamterene
sulfamethoxazole will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
triamterene, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.
triamterene increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown. - trimethoprim
sulfamethoxazole will increase the level or effect of trimethoprim by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- trimipramine
sulfamethoxazole decreases levels of trimipramine by unspecified interaction mechanism. Minor/Significance Unknown.
- valganciclovir
valganciclovir increases toxicity of sulfamethoxazole by pharmacodynamic synergism. Minor/Significance Unknown.
- valproic acid
valproic acid will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- verapamil
sulfamethoxazole will increase the level or effect of verapamil by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- verteporfin
sulfamethoxazole, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity.
- voriconazole
sulfamethoxazole will increase the level or effect of voriconazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
voriconazole will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown. - willow bark
willow bark increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- zafirlukast
zafirlukast will increase the level or effect of sulfamethoxazole by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.
- zidovudine
zidovudine increases toxicity of sulfamethoxazole by pharmacodynamic synergism. Minor/Significance Unknown.
sulfamethoxazole increases levels of zidovudine by decreasing renal clearance. Minor/Significance Unknown.
